BioTuesdays

Category - Markets

Scynexis Logo
Markets

Brookline starts SCYNEXIS at buy; PT $5

Brookline Capital Markets launched coverage of SCYNEXIS (NASDAQ:SCYX) with a “buy” rating and $5 price target. The stock closed at $1.07 on Aug. 19. Analyst Kumaraguru Raja writes that SCYNEXIS’ lead product candidate...

August 20, 2019
Markets

HCW starts Entasis Therapeutics at buy; PT $18

H.C. Wainwright initiated coverage of Entasis Therapeutics (NASDAQ:ETTX) with a “buy” rating and $18 price target. The stock closed at $8.25 on Aug. 16. Spun out of AstraZeneca in 2015, Entasis is focused on novel...

August 19, 2019
Markets

SVB Leerink starts Myovant Sciences at OP; PT $26

SVB Leerink initiated coverage of Myovant Sciences (NYSE:MYOV) with an “outperform” rating and $26 price target. The stock closed at $7 on Aug. 16. “Myovant’s lead product, relugolix, is poised to become the second...

August 19, 2019
Markets

Dawson James starts BeyondSpring at buy; PT $39

Dawson James Securities initiated coverage of BeyondSpring (NASDAQ:BYSI) with a “buy” rating and price target of $39. The stock closed at $16.21 on Aug. 15. “BeyondSpring’s [flagship molecule] Plinabulin is well...

August 16, 2019
Markets

Brookline starts Vaxart at buy; PT $6

Brookline Capital Markets launched coverage of Vaxart (NASDAQ:VXRT) with a “buy’ rating and $6 price target. The stock closed at 66 cents on Aug. 14. Vaxart is focused on oral, recombinant vaccines that are expected to...

August 15, 2019
Markets

HCW ups Cesca Therapeutics PT to $6.50 from $1

H.C. Wainwright raised its price target for Cesca Therapeutics (NASDAQ:KOOL) to $6.50 from $1 after the company’s second quarter revenue beat consensus. The stock closed at $3 on Aug. 13. Cesca develops and markets...

August 14, 2019
Mustang Bio Logo
Markets

HCW starts Mustang Bio at buy; PT $7

H.C. Wainwright initiated coverage of Mustang Bio (NASDAQ:MBIO) with a “buy” rating and $7 price target. The stock closed at $2.89 on Aug. 12. Analyst Joseph Pantginis writes that Mustang is developing multiple novel...

August 13, 2019
Ra Medical
Markets

Piper cuts Ra Medical to neutral; PT to $1.50 from $9

Piper Jaffray downgraded Ra Medical Systems (NASDAQ:RMED) to “neutral” from “overweight” and slashed its price target to $1.50 from $9 after the company disclosed several operating issues in its preliminary second...

August 13, 2019